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 2012 EMBO Molecular MedicineInduced pluripotent stem cells (iPSC) offer an unprecedented opportunity to
model human disease in relevant cell types, but it is unclear whether they could
successfully model age-related diseases such as Parkinson’s disease (PD). Here,
we generated iPSC lines from seven patients with idiopathic PD (ID-PD), four
patients with familial PD associated to the G2019S mutation in the Leucine-Rich
Repeat Kinase 2 (LRRK2) gene (LRRK2-PD) and four age- and sex-matched healthy
individuals (Ctrl). Over long-time culture, dopaminergic neurons (DAn) differen-
tiated from either ID-PD- or LRRK2-PD-iPSC showed morphological alterations,
including reduced numbers of neurites and neurite arborization, as well as
accumulation of autophagic vacuoles, which were not evident in DAn differen-
tiated from Ctrl-iPSC. Further induction of autophagy and/or inhibition of
lysosomal proteolysis greatly exacerbated the DAn morphological alterations,
indicating autophagic compromise in DAn from ID-PD- and LRRK2-PD-iPSC,
which we demonstrate occurs at the level of autophagosome clearance. Our
study provides an iPSC-based in vitro model that captures the patients’ genetic
complexity and allows investigation of the pathogenesis of both sporadic and
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Parkinson’s disease (PD) is a common and devastating
neurodegenerative disorder characterized by motor clinical
manifestations, although non-motor features are also important
in later stages of the disease (Lees et al, 2009; Obeso et al, 2010;
Schapira & Tolosa, 2010). Movement alterations in PD stem
from the selective loss of dopaminergic neurons (DAn) from the
pars compacta of the substantia nigra, a specific subtype of
neurons patterned as ventral midbrain DAn (vmDAn). Neuronal
loss is typically progressive and accompanied by a-synuclein
(SNCA)-containing intraneuronal inclusions known as Lewy
bodies and Lewy neurites. While the majority of PD cases are
sporadic, likely resulting from complex interactions among gene
susceptibility and environmental factors, around 10% of
patients present monogenic forms of the disease (Lesage &
Brice, 2009). Pathogenic mutations in the Leucine-Rich Repeat
Kinase 2 (LRRK2) and SNCA genes have been identified and
associated to PD, while mutations in four genes (Parkin, DJ-1,
PINK1 and ATP13A2) cause early onset parkinsonism (Lees
et al, 2009). In particular, LRRK2 mutations cause an autosomal
dominant, late-onset familial PD, whose clinical and patholo-
gical features are indistinguishable from those of the common,
sporadic form of PD (Paisan-Ruiz et al, 2004; Zimprich et al,
2004). While over 50 variants have been identified throughout
the different LRRK2 domains in PD patients, the mutation
G2019S has been regarded as the most common cause of
dominant familial PD and accounts for up to 2% of sporadic PD
cases (Cookson, 2010).
The pathogenic mechanisms that lead to neurodegeneration
in PD are not well understood, since current experimental PD
models do not recapitulate key neuropathological features of the
disease (Dawson et al, 2010). In particular, the special
susceptibility of DAn to neurodegeneration and the progressive
nature of this process in PD, together with the presence of Lewy
bodies, have proven especially difficult to model in animal
models of PD. The advent of induced pluripotent stem cell
(iPSC) technology (Takahashi & Yamanaka, 2006) has made it
possible to reprogram human somatic cells to pluripotency
(Park et al, 2008b; Takahashi et al, 2007; Yu et al, 2007), thus
enabling the generation of disease-specific iPSC (Lee & Studer,
2010). In this way, disease-relevant cell types have been
generated from iPSC representing a variety of early onset
diseases, and shown to display specific features of the disease
in vitro (Carvajal-Vergara et al, 2010; Ebert et al, 2009; Ku et al,
2010; Lee et al, 2009; Marchetto et al, 2010; Moretti et al, 2010;
Rashid et al, 2010; Raya et al, 2009; Zhang et al, 2011). Disease-
specific iPSC have also been generated from sporadic cases of
PD, but DAn differentiated from these cells did not show any
conspicuous phenotype (Soldner et al, 2009), prompting
uncertainty as to whether iPSC technology might be useful to
model diseases of non-monogenic, complex etiology and/or late
onset. Here, we generated iPSC lines from both idiopathic PD
(ID-PD) and familial PD associated to the G2019S mutation in
the LRRK2 gene (the most frequent cause of familial PD,
Cookson, 2010), as well as from age- and sex-matched healthy
individuals. We show that, over long-time culture, DAnwww.embomolmed.org EMBO Mol Med 4, 380–395differentiated from PD-iPSC display specific PD pathology
related phenotypes and, thus, provide proof-of-concept for
iPSC-based cellular models that capture PD patients’ genetic
complexity and allow investigation of the PD pathogenesis in
disease-relevant cell types.RESULTS
Generation of PD-specific iPS cell lines
We recruited a total of 15 individuals into this study: 7 patients
diagnosed with ID-PD, with no family history of disease and no
known PD-related mutations; 4 unrelated patients diagnosed
with familial PD carrying the G2019S mutation in the LRRK2
gene (LRRK2-PD); and 4 healthy individuals with no history of
neurological disease (Ctrl). Individuals in each group were also
selected so that no significant bias in gender or age occurred
(Table 1). Primary cultures of epidermal keratinocytes and
dermal fibroblasts were established from all individuals
and were used for reprogramming at passages 2–4. We used
retroviral delivery of OCT4, KLF4 and SOX2 to generate 2–6
independent iPSC lines per individual, totalling 50 iPSC lines. Of
those, 2 lines per patient were thoroughly characterized and
shown to be fully reprogrammed to pluripotency, as judged by
colony morphology and growth dynamics, sustained long-term
passaging (>20 passages), karyotype stability, alkaline phos-
phatase (AP) staining, expression of pluripotency associated
transcription factors (OCT4, SOX2, NANOG, CRIPTO and REX1)
and surface markers (SSEA3, SSEA4, TRA1-60 and TRA1-81),
silencing of retroviral transgenes, demethylation of OCT4 and
NANOG promoters, in vitro pluripotent differentiation ability
and generation of teratomas comprising derivatives of the three
main embryo germ layers (Table 1 and Fig 1A–N).
The efficiency of iPSC generation varied among different
individuals, but did not depend on the presence or type of
disease, nor on the age of donors. Whereas, most of the iPSC
lines analyzed met our criteria for bona fide pluripotent stem
cells, those that failed to silence the reprogramming transgenes,
did not differentiate appropriately in vitro, or presented
karyotype alterations were identified and excluded from further
studies (Table 1). Overall, iPSC generated from PD patients or
from healthy individuals were indistinguishable in all tests
performed, with the exception that LRRK2-PD iPSC lines carried
the LRRK2G2019S mutation (Fig 1O).
Generation of PD-specific vmDA neurons
For the directed differentiation of iPSC towards vmDA neurons
(the cell type most affected in PD), we used a 30-day protocol
recently implemented in our laboratory that relies on lentiviral-
mediated forced expression of the ventral midbrain determinant
LMX1A, together with DA neuron patterning factors (Sanchez-
Danes et al, 2012). All iPSC lines tested generated DAn using this
differentiation protocol, as judged by co-staining with the
neuron-specific class III-b-tubulin (TUJ1) and tyrosine hydro-
xylase (TH; Fig 2A–C). Moreover, DAn differentiated in this way
were mature and mostly of the A9 subtype, as revealed by
expression of dopamine transporter (DAT), G protein-activated 2012 EMBO Molecular Medicine 381
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Table 1. Summary of iPSC lines generated
Patient Disease iPSC




















CONTROL SP09 M 66 4 SP09.2 46,XY Passed Passed Passed N/P
SP09.4 46,XY Passed Passed Passed Passed
SP11 F 48 3 SP11.1 46,XX Passed Passed Passed Passed
SP11.4 46,XX Passed Passed Passed N/P
SP15 F 47 4 SP15.2 46,XX Passed Passed Passed Passed
SP15.3 46,XX Passed Passed Passed N/P
SP15.4 47,XXþ20 Passed Passed N/P N/P
SP17 M 52 3 SP17.1 47,XYþ20 Passed Passed Passed N/P
SP17.2 46,XY Passed Passed Passed Passed
SP17.3 46,XY Passed Passed Failed N/P
ID-PD SP01 F 63 58 No No T and B N/A 4 SP01.1 46,XX Passed Passed Passed Passed
SP01.4 46,XX Passed Passed Passed N/P
SP02 M 55 48 No No T N/A 2 SP02.1 46,XY Passed Passed Passed Passed
SP02.2 46,XY Passed Passed Passed N/P
SP04 M 46 40 No No B Good 2 SP04.1 46,XY Passed Passed Passed N/P
SP04.2 46,XY Passed Passed Passed Passed
SP08 F 66 60 No No T Good 4 SP08.1 46,XX Passed Passed Passed Passed
SP08.2 46,XX Passed Passed Passed N/P
SP08.3 46,XX Failed N/P N/P N/P
SP10 M 58 50 No No D Good 2 SP10.1 46,XY Passed Passed Passed N/P
SP10.2 46,XY Passed Passed Passed Passed
SP14 M 55 51 No No B Good 2 SP14.1 46,XY Passed Passed Passed Passed
SP14.2 46,XY Passed Passed Passed N/P
SP16 F 51 48 No No B N/A 4 SP16.2 46,XX Passed Passed Passed Passed
SP16.3 46,XX Passed Passed Passed N/P
LRRK2-PD SP05 M 66 52 Yes LRRK2 B Good 2 SP05.1 46,XY Passed Passed Passed Passed
SP05.2 46,XY Passed Passed Passed N/P
SP06 M 44 33 Yes LRRK2 T Good 6 SP06.1 46,XY Passed Passed N/P N/P
SP06.2 46,XY Passed Passed Passed Passed
SP12 F 63 49 Yes LRRK2 T Good 4 SP12.3 46,XX Passed Passed Passed Passed
SP12.4 46,XX Passed Passed Passed N/P
SP13 F 68 57 Yes LRRK2 T Good 4 SP13.2 46,XX Passed Passed Passed N/P
SP13.4 46,XX Passed Passed Passed Passed
N/A, information not available; N/P, test not performed.
aAge at biopsy.
bT, tremor; B, bradykinesia; D, foot dystonia.
cTests performed as exemplified in Fig 1.
382inward rectifier potassium channel 2 (GIRK2) and FOXA2,
respectively (Fig S1 of Supporting information). We found a
large variability in the numbers of DAn obtained from different
iPSC lines, ranging from 9 to 29% of all differentiated cells,
which did not depend on the presence or type of disease
(Fig 2D), nor on the efficiency of lentiviral infection (Fig S2 of
Supporting information), but rather appeared to depend on the
specific iPSC clone used (Fig S3 of Supporting information),
consistent with previous results on differentiation to other
neuronal lineages (Hu et al, 2010). Thus, our results so far
confirm previous data on the similar ability of control and ID-PD
iPSC to give rise to DAn (Soldner et al, 2009, 2011) and extend
these findings to iPSC derived from LRRK2-PD patients.
Spontaneous phenotypes of PD-specific vmDA neurons
Because SNCA is the main component of Lewy bodies, and
immunolabelling with antibodies against SNCA has become the
standard and most sensitive immunohistochemical method for
the neuropathological diagnosis of PD (Lees et al, 2009), we first
investigated whether SNCA could be detected in DAn differ-
entiated from PD-specific iPSC. The majority of DAn differ- 2012 EMBO Molecular Medicineentiated from Ctrl-iPSC and ID-PD iPSC exhibited barely
detectable levels of endogenous SNCA in their cytoplasm,
while20% of DAn showed cytoplasmic staining (Fig 3A, B and
D). However, most DAn derived from LRRK2-PD iPSC exhibited
diffuse cytoplasmic accumulations of SNCA (Fig 3C and D),
which did not form obvious aggregates or inclusions. This
finding is consistent with results from animal studies that
reported post-translational regulatory interactions of mutant
LRRK2 and SNCA (reviewed in Cookson, 2010). In this line, the
accumulation of SNCA in our model of LRRK2-PD iPSC-derived
DAn did not appear to depend on transcriptional regulation of
SNCA expression, which was upregulated during DAn differ-
entiation to a similar extent compared with Ctrl-iPSC- and ID-PD
iPSC-derived cells (Fig S4 of Supporting information), which
also showed similar LRRK2 levels (Fig S5 of Supporting
information).
Since neuronal degeneration in PD patients takes decades to
occur, we next attempted to maintain iPSC-derived DAn over
longer culture times. For this purpose, we co-cultured them over
a monolayer of mouse post-natal cortical astrocytes (Johnson
et al, 2007), which supported viable cultures of vmDA neuronsEMBO Mol Med 4, 380–395 www.embomolmed.org
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Figure 1. Generation and characterization of PD patient-specific iPSC lines.
A-C. Representative colonies of passage-20 LRRK2-PD-iPSC (cell line SP13.4) stained positive for the pluripotency-associated markers NANOG, OCT4 and SOX2
(green), TRA-1-81, SSEA3 and SSEA4 (red).
D-F. Immunofluorescence analyses of LRRK2-PD-iPSC (cell line SP13.4) differentiated in vitro show the potential to generate cell derivatives of all three primary
germ cell layers including ectoderm (D, stained for TUJ1, green), endoderm (E, stained for a-fetoprotein, green, and FOXA2, red) and mesoderm (F, stained for
smooth muscle actin, SMA, red).
G-I. Immunofluorescence analyses of sections from a teratoma induced by injecting LRRK2-PD-iPSC (cell line SP13.4), showing derivatives of the three main
embryo germ layers: ectoderm (G, stained for TUJ1, green, and GFAP, red), endoderm (H, stained for a-fetoprotein, green, and FOXA2, red) and mesoderm
(I, stained for SOX9, green, and chondroitin sulphate, CS, red). In (A–I) nuclei are counterstained with DAPI, shown in blue. Scale bars, 50mm.
J. LRRK2-PD-iPSC (cell line SP13.4) stained for alkaline phosphatase (AP) activity.
K. Normal karyotype of LRRK2-PD-iPSC (cell line SP13.4) at passage 20.
L. Bisulphite genomic sequencing of the OCT4 and NANOG promoters showing demethylation in LRRK2-PD-iPSC (cell line SP13.4).
M. Southern blot analysis of LRRK2-PD-iPSC (cell line SP13.4) showing genomic integrations (asterisk) of the indicated retroviruses.
N. RT-qPCR analyses of the expression levels of retroviral-derived reprogramming factors (transgenic) and endogenous expression levels (endogenous) of the
indicated genes in LRRK2-PD-iPSC (cell line SP13.4).
O. Direct sequence of genomic DNA from LRRK2-PD-iPSC (cell line SP13.4) identifying the LRRK2G2019S mutation.for up to 75 days (latest time point analysed, see Fig S6 of
Supporting information). Under these conditions, Ctrl-iPSC gave
rise to DAn that were morphologically homogeneous and
showed the expected features of mature DAn, including
complex dendritic arborizations (Fig 4A and F). However,
DAn differentiated from ID-PD or LRRK2-PD iPSC developed a
range of altered morphologies over long-term culture that were
not evident at shorter time points (Fig S7 of Supporting
information). After detailed analysis, we categorized the
morphologies of individual DAn in these cultures in three
types: type 1 were neurons with mature morphology and long
neurites with complex arborization, similar to those differ-
entiated from Ctrl-iPSC; type 2 DAn showed fewer and simplerwww.embomolmed.org EMBO Mol Med 4, 380–395processes, reminiscent of immature neurons; and type 3 were
DAn with clear signs of degeneration, including very short or
absent neurites, vacuolated soma, fragmented nucleus and
positive staining for cleaved caspase-3 (Fig 4A–D and Fig S7
of Supporting information). In aged (75 days) cultures, most of
DAn differentiated from ID-PD or LRRK2-PD iPSC were of
altered type 2 or type 3 morphologies (Fig S7 of Supporting
information), with a significant percentage of them undergoing
apoptosis (Fig 4E).
To rule out any subjectivity that might have occurred in the
adscription of different morphologies to iPSC-derived DAn, we
also directly measured the number and length of neurites. For
this, we used high-power confocal images of TH-stained single 2012 EMBO Molecular Medicine 383
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Figure 2. Differentiation of DA neurons from PD patient-specific iPSC. Ctrl-, ID-PD and LRRK2-PD iPSC were differentiated into DA neurons and analysed by
immunofluorescence for expression of TUJ1 (green) and TH (red) at the end of the 30-day differentiation protocol.
A-C. All iPSC-derived neurons express TUJ1 and TH. Shown are representative images of differentiation experiments from Ctrl-iPSC (cell line SP11.1), ID-PD iPSC
(cell line SP08.1) and LRRK2-PD iPSC (cell line SP06.2). Nuclei are counterstained with DAPI, shown in blue. Scale bars, 50mm.
D. Quantitative analyses of cells stained positive for TUJ1 (left bars) or TUJ1 and TH (right bars). TUJ1-positive cells are represented as the percentage of total
number of cells (stained with DAPI). Bars represent average with SEM as error bars. Data for CONTROL is the average of 4 iPSC lines, for ID-PD from 7 iPSC
lines and LRRK2-PD from 4 iPSC. No significant differences were found in the ability of iPSC to generate neurons [F(2,12)¼0.953; p¼0.413] or DA neurons
[F(2,12)¼ 0.679; p¼ 0.526] after 30 days of differentiation.
384neurons, randomly chosen, differentiated from all the PD
patient-specific and control iPSC lines and used software-
assisted analysis (Fig 4F, see also Chu et al, 2009). These
analyses confirmed that both the number and length of neurites
of Ctrl-iPSC-derived DAn were significantly higher than those of
DAn differentiated from ID-PD or LRRK2-PD iPSC (Fig 4G and
H). The causative role of the genetic background of patient-
specific cells was further investigated by ectopically expressing
mutated LRRK2G2019S in DAn differentiated from Ctrl-iPSC. In
these experiments, DAn differentiated for 65 days were co-
transfected with plasmids encoding wild-type (WT) LRRK2 or
LRRK2G2019S and GFP, and cells were analysed after 10 days. 2012 EMBO Molecular MedicineEven though the transfection efficiency (as evaluated by GFP/
TH double positive cells) was low in all cases, we could readily
detect DAn transfected with WT LRRK2, which were morpho-
logically indistinguishable from untransfected DAn (Fig 4I–K
and M). In contrast, few DAn transfected with mutant
LRRK2G2019S were found after 10 days, suggesting that the
expression of pathogenic LRRK2 is deleterious for these cells
(Fig 4M). Indeed, surviving DAn expressing mutated
LRRK2G2019S displayed evident morphological alterations,
including fewer and shorter neurites compared to untransfected
DAn or DAn expressing WT LRRK2 (Fig 4I–L and N). So far, our
data show that, even though PD-specific iPSC differentiateEMBO Mol Med 4, 380–395 www.embomolmed.org
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Figure 3. Abnormal SNCA accumulation in DA neurons from LRRK2-PD
iPSC.
A-C. Immunofluorescence analyses of DA neurons after 30 days of differen-
tiation from Crtl-iPSC (A), ID-PD iPSC (B) and LRRK2-PD iPSC (C), co-
stained for TH (green) and SNCA (red). Arrows point to DA neurons, as
identified by TH positive staining.
D. Quantitative analyses of DA neurons showing cytoplasmic accumulation
of SNCA. Bars represent average with SEM as error bars. Data is the
average of at least two-independent experiments using 3 Ctrl-iPSC lines,
4 ID-PD iPSC lines and 3 LRRK2-PD iPSC lines. The differences in the
number of DA neurons showing accumulation of SNCA are statistically
significant (asterisk) when comparing those derived from LRRK2-PD iPSC
with either those from Ctrl-iPSC (p¼0.019) or from ID-PD iPSC
(p¼ 0.002) [F(2,16)¼ 6.888; p¼ 0.007].normally into vmDA neurons, they display evident signs of
morphological alterations upon long-time culture.
Impaired autophagy of PD-specific vmDA neurons
We next investigated the bases for the altered morphology and
shorter/fewer neurites of PD iPSC-derived DAn compared to
those differentiated from Ctrl-iPSC. Given that autophagy has
been shown to play key roles for maintaining neurite length
(reviewed in Chu et al, 2009) and that several lines of evidence
indicate that dysregulated autophagy may be a pathogenic
mechanism in PD (Menzies et al, 2011), we first analysed the
autophagosome content in iPSC-derived DAn. For this purpose,
we used immunofluorescence labelling with antibodies to the
light chain type 3 protein (LC3), a marker of autophagosomeswww.embomolmed.org EMBO Mol Med 4, 380–395(Kabeya et al, 2000). After 75 days of culture, DAn differentiated
from Ctrl-iPSC showed a diffuse cytoplasmic LC3 staining with
very few autophagosomes (LC3-positive puncta, Fig 5A). In
contrast, a marked increase in LC3-positive puncta was evident
in untreated DAn differentiated from ID-PD or LRRK2-PD iPSC
(Fig 5B–E). The fact that autophagosomes were evident even in
the absence of inhibitors of lysosomal proteolysis in these
neurons suggests either massive upregulation of autophago-
some formation, or a compromise in the clearance of autophagic
compartments in these cells. To distinguish between these
possibilities, we compared levels of p62 in the three groups of
cells. A large fraction of p62 undergoes degradation through
autophagy because it serves as a cargo-recognizing protein that
it is sequestered in autophagosomes along the cytosolic cargo.
Immunostaining for p62 revealed a marked increase in the levels
of this protein in DAn differentiated from ID-PD or LRRK2-PD
iPSC, where it showed a punctuate pattern reminiscent of the
one observed for LC3 (Fig 5F–J).
To directly analyse autophagic clearance we compared the
rates of degradation of LC3-II in the different cells by
immunoblot (LC3-flux assay), even though we were aware
that neural-specific changes could be underestimated in this
type of analysis, as DAn represent only a fraction of the cells
present in whole-culture lysates. Part of the LC3 located in the
inner membrane of the autophagosome is degraded along with
the cargo when these compartments fuse to lysosomes,
consequently the increase in levels of LC3-II upon blockage
of lysosomal proteolysis provides information on autophagic
clearance. As expected, immunoblot for LC3 confirmed an
increase in basal steady-state levels of LC3-II in the PD-derived
cells (Fig 5K and L). Blockage of lysosomal degradation resulted
in an increase in LC3-II levels in all cells but, despite some level
of individual variability, the autophagic flux was significantly
reduced in PD-derived cells (Fig 5K and M). To separately
analyse autophagosome formation independently of clearance,
we also compared changes in LC3-II at two different times after
blockage of lysosomal degradation (under these conditions, any
increase in LC3-II would directly result from autophagosome
formation as degradation is no longer occurring). Although we
found a consistent trend for increased autophagosome forma-
tion in DAn differentiated from ID-PD or LRRK2-PD, when
compared to Crtl-iPSC (Fig 5K and N), this increase was not
statistically significant and clearly less pronounced that the
changes observed on clearance. Our findings thus support that
the marked increase in the abundance of these compartments in
PD-iPSC-derived neurons when compared with control was due,
for the most part, to blockage on their clearance.
Ultrastructural analysis by electron microscopy confirmed
marked differences in the autophagic system between DAn
differentiated from Ctrl-iPSC and those of PD origin. As shown in
Fig 6A–C, autophagic vacuoles were in general more abundant
in the PD groups. In control cells, most of the autophagic profiles
corresponded to autophagolysosomes (autophagic vacuoles
already fused to lysosomal compartments; Fig 6A and D). In
contrast, in the case of the ID-PD and LRRK2-PD, autophago-
somes (prior to lysosomal fusion) were predominant (Fig 6B–
D), supporting that the increase in LC3-positive structures is 2012 EMBO Molecular Medicine 385
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Figure 4.
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~likely due to problems in the maturation of autophagosomes. An
increase in intracellular lipid droplets, previously shown to
undergo degradation by macroautophagy (Singh et al, 2009),
and the presence of dilated ER in the PD cells are also common
features of cells with compromised autophagy (Fig 6B, C and E).
Lastly, defective autophagosome clearance was also con-
firmed analyzing the co-localization of autophagosome (LC3)
and lysosomal (LAMP-1) markers in DAn differentiated from ID-
PD, LRRK2-PD or Crtl-iPSC. The very low levels of LC3 puncta
detected in basal conditions in the control cells (Fig S8 of
Supporting information) precluded evaluating LC3/LAMP-1
co-localization in these cells. To be able to compare the
autophagic flux among the three groups of cells, we reduced
degradation of LC3 in lysosomes by treatment with leupeptin
(which does not modify autophagosome/lysosome fusion).
Under these conditions, we detected a significantly lower level
of LC3/LAMP-1 co-localization in both ID-PD and LRRK2-PD
iPSC-derived DAn, when compared to control cells (Fig 7A–D).
These results confirm compromised maturation of autophago-
somes into autophagolysosomes in these cells.
To evaluate whether morphological alterations and autop-
hagy defects in DAn were mechanistically linked, we next
reproduced in Ctrl-iPSC-derived DAn the blockage of autophagic
clearance observed in ID-PD and LRRK2-PD iPSC, by inducing
autophagosome formation through mTOR inhibition with
rapamycin and, at the same time, blocking lysosomal degrada-
tion with leupeptin. This treatment resulted in 20% of Ctrl-
iPSC-derived DAn showing higher number of autophagosomes,
which stained positive for LC3 as well as for LAMP-1 (Fig S9 of
Supporting information). This combined treatment had an even
more marked effect in DAn differentiated from ID-PD or LRRK2-
PD iPSC. In either case, rapamycin/leupeptin treatment induced
a significant shortening in the average total neurite length of
DAn (Fig 7E). Importantly, the increased susceptibility of ID-PD
and LRRK2-PD iPSC-derived DAn to rapamycin/leupeptinFigure 4. Morphological alterations of PD-iPSC-derived DA neurons after long
A-C. Immunofluorescence analyses of Ctrl-iPSC (cell line SP11.1, A), ID-PD iPSC (ce
DA neurons and cultured for 75 days on cortical astrocytes, stained for TH (r
under these conditions.
D. Immunofluorescence analysis of DA neurons differentiated from LRRK2-PD iP
(green). In A–D nuclei are counterstained with DAPI, shown in blue. Scale b
E. Quantitative analyses of the percentage of DA neurons differentiated for 75 d
iPSC lines, for ID-PD from 7 iPSC lines and LRRK2-PD from 4 iPSC. Asterisks
(p¼ 0.004) or LRRK2-PD (p¼ 0.011) [F(2,12)¼5.668; p¼0.018].
F. Image of the same DA neuron shown in (A), with neurites outlined by gree
G. Quantitative analyses of the number of neurites in DAn differentiated for 75 d
from 119 DAn from 7 iPSC lines and for LRRK2-PD is from 91 DAn from 4 iPSC.
PD (p<0.001) or LRRK2-PD (p<0.001) [F(2,294)¼ 21.096; p<0.001].
H. Quantitative analyses of the neurite length in DA neurons differentiated for 7
ID-PD is from 409 neurites from 7 iPSC lines and for LRRK2-PD is from 303 neu
CONTROL and ID-PD (p<0.001) or LRRK2-PD (p<0.001) [F(2,1249)¼42.1
I-L. DAn (TH positive, red) and GFP (green) from Ctrl-iPSC (SP11.1) co-transfected w
and GFP. (I and J) Images showing GFP negative DA neurons. (K and L) Co-tra
shown in blue. Scale bar, 12.5mm.
M. Quantitative analysis of the number of GFP positive neurons present in co-
N. Quantitative analyses of the neurite length per neuron in co-transfected DAn
different Ctrl-iPSC lines. Bars represent average with SEM as error bars. Sta
p¼0.006 in N).
www.embomolmed.org EMBO Mol Med 4, 380–395treatment appeared to be cell type-specific, since patients’
fibroblasts showed an increase of LC3-positive puncta and
changes in LC3 levels comparable to control cells upon this
treatment (Fig S10 of Supporting information), further support-
ing that the compromise in autophagosome clearance may be
specific for DAn. These results indicate that DAn differentiated
from either ID-PD or LRRK2-PD iPSC have a deficient
competence for autophagic clearance compared with Ctrl-
iPSC-derived DAn, and suggest that the PD pathology related
phenotypes revealed in our in vitro model are caused, at least in
part, by an impairment in the autophagy pathway.DISCUSSION
In this study, we describe the generation and characterization of
a collection of iPSC lines representing age- and sex-matched
patients of sporadic and LRRK2-associated PD, as well as control
individuals. Consistent with previous studies describing the
generation of patient-specific iPSC in the context of PD (Park
et al, 2008a; Soldner et al, 2009, 2011) or other conditions
(Dimos et al, 2008; Park et al, 2008a; Raya et al, 2010), the
efficiency of iPSC generation varied among different individuals,
but did not depend on the presence or type of disease, nor on the
donor age. We chose retroviral delivery of reprogramming
transgenes to secure the derivation of iPSC lines from valuable
biopsy material, because of the higher efficiency of this system
in our hands compared to that of lentivirus-based systems. A
clear advantage of the latter is the possibility of using inducible
excisable lentivirus (Soldner et al, 2009), so that iPSC are free of
reprogramming transgenes. However, we reasoned that a
careful analysis of the silencing of integrated transgenes in
our iPSC lines, together with the generation of independent iPSC
lines from several patients representing each condition, would
rule out any confounding effects due to residual transgene-term culture.
ll line SP08.1, B) and LRRK2-PD iPSC (cell line SP06.2, C), differentiated towards
ed). Images are representative of the three morphologies of DA neurons found
SC (cell line SP06.2) for 75 days, co-stained for TH (red) and cleaved caspase-3
ar, 12.5mm.
ays showing cleaved caspase-3 staining. Data for CONTROL is the average of 4
denote statistically significant differences between CONTROL and ID-PD
n traces as processed by NIH ImageJ software.
ays. Data for CONTROL is the average of 87 DAn from 4 iPSC lines, for ID-PD is
Asterisks denote statistically significant differences between CONTROL and ID-
5 days. Data for CONTROL is the average of 540 neurites from 4 iPSC lines, for
rites from 4 iPSC. Asterisks denote statistically significant differences between
61; p< 0.001]. (E, G and H) bars represent average with SEM as error bars.
ith plasmids encoding WT LRRK2 (WT, I and K) or mutant LRRK2G2019S (J and L)
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Figure 5. Alterations in autophagic clearance in DA neurons from PD patient-specific iPSC.
A-E. Immunofluorescence analyses of Ctrl-iPSC (cell line SP17.2, A), ID-PD iPSC (cell line SP16.2, B and C) and LRRK2-PD iPSC (cell line SP12.3, D and E),
differentiated towards DA neurons and cultured for 75 days on cortical astrocytes, co-stained for LC3 (green) and TH (red). Images are representative of the
most abundant morphologies of DA neurons found under these conditions.
F-J. Immunofluorescence analyses of Ctrl-iPSC (cell line SP17.2, F), ID-PD iPSC (cell line SP10.2, G and H) and LRRK2-PD iPSC (cell line SP06.2, I and J),
differentiated towards DA neurons and cultured for 75 days on cortical astrocytes, co-stained for p62 (green) and TH (red). Images are representative of the
morphologies of DA neurons found under these conditions. In A–J, nuclei are counterstained with DAPI, shown in blue. Scale bars, 35mm.
K. Western blot analysis for LC3 in DA neuron cultures at 75 days of differentiation from the indicated iPSC lines, treated with leupeptin and NH4Cl during the
indicated period of time. a-tubulin is used as a loading control.
L. Quantification analyses of the basal levels (treatment time¼ 0) of LC3-II relative to a-tubulin. Asterisks denote statistically significant differences between
CONTROL and ID-PD (p¼0.003) and between CONTROL and LRRK2-PD (p¼ 0.046) [F(2,12)¼4.253; p¼0.046].
M. Quantification of LC3 flux normalized to a-tubulin. Asterisks denote statistically significant differences between CONTROL and ID-PD (p¼0.002) and
between CONTROL and LRRK2-PD (p¼0.029) [F(2,12)¼9.614; p¼0.003].
N. Quantification of the autophagosome formation normalized to a-tubulin. No significant differences were found among groups [F(2,12)¼1.570; p¼ 0.248].
(L–N) Data per each group is the average of the blots shown in K. Bars represent average with SEM as error bars.
388expression in individual iPSC lines, while still allowing a high
efficiency of iPSC generation. In any case, we omitted c-MYC
from the reprogramming cocktail due to the possibility of its
interaction with LRRK2 in the context of eukaryotic initiation
factor 4E (eIF4E) function regulation (Imai et al, 2008; Ruggero
et al, 2004).
All the iPSC lines tested in our study were competent to give
rise to DAn, although the efficiency at which they did so varied
among lines. Similar findings have been reported for iPSC in a
variety of differentiation protocols, including neuronal lineages
other than DAn (Hu et al, 2010), cardiomyocytes (Zhang et al,
2009) and haematopoietic cells (Woods et al, 2011). Impor-
tantly, the variability in differentiation efficiency of our iPSC
lines was independent of the presence or type of disease,
indicating inter-line variation, rather than a result of the disease.
Moreover, DAn differentiated from Ctrl- or PD-iPSC appeared
morphologically and phenotypically indistinguishable after 2012 EMBO Molecular Medicine30 days in culture, in agreement with a previous report that
analysed the DAn differentiation ability of IP-PD iPSC (Soldner
et al, 2009), and extending these findings to iPSC derived from
LRRK2-PD patients. Despite this similarity, we found anomalous
accumulation of SNCA in DAn differentiated from LRRK2-PD
iPSC, compared to those from Ctrl- or ID-PD iPSC. The
identification of this PD-related phenotype in LRRK2 mutant
DAn is consistent with the notion that LRRK2 and SNCA may
participate in intersecting pathways (reviewed in Cookson,
2010), and with the fact that LRRK2 can accelerate mutant
SNCA-induced neuropathology in mice in a dose-dependent
manner (Lin et al, 2009). Moreover, these results demonstrate
the ability of iPSC-based cellular systems to recapitulate PD-
related pathology and to model a monogenic form of PD.
Probably the most significant finding of our work is the
identification of spontaneous phenotypes in long-term cultures
of DAn from both idiopathic and LRRK2-associated PD. To ourEMBO Mol Med 4, 380–395 www.embomolmed.org
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Figure 6. Autophagic system in iPSC-derived neurons.
A-C. Ultrastructure of DA neurons at 75 days of differentiation from Ctrl-iPSC (A), ID-PD iPSC (B) and LRRK2-PD (C) iPSC. Lower inserts show higher magnification
images to illustrate individual examples of autophagic vacuoles. Black arrows: autophagosomes; white arrows: autophagolysosomes; arrowheads: dilated
ER; LD: lipid droplets. Scale bars: 0.5mm (top) and 0.2mm (bottom).
D. Percentage of autophagosomes (APG) and autophagolysosomes (APGL) relative to the total amount of autophagic vacuoles per field. Asterisks denote
statistically significant differences in the percentage of autophagosomes [F(2,16)¼28.274; p< 0.001] and of autophagolysosomes [F(2,16)¼8.894;
p¼0.003] between CONTROL and ID-PD (autophagosomes, p<0.001; autophagolysosomes, p¼0.003), and between CONTROL and LRRK2-PD (autop-
hagosomes, p¼0.003; autophagolysosomes, p¼0.010).
E. Content of lipid droplets per field. Asterisks denote statistically significant differences [F(2,16)¼ 28.274; p<0.001] between CONTROL and ID-PD
(p¼ 0.010), and between CONTROL and LRRK2-PD (p¼ 0.013). Bars represent average with SEM as error bars (n¼4–8).knowledge, this is the first time such phenotypes have been
described. Indeed, Soldner and colleagues did not find any
differences between DAn differentiated from ID-PD iPSC and
from control iPSC (Soldner et al, 2009), a fact that they attributed
to the short time span of cultured neurons (32–42 days).
Moreover, these authors suggested that additional manipula-
tions might be necessary to accelerate PD-pathology related
phenotypes in iPSC-derived DAn in vitro, such as increasing
oxidative stress, challenge with neurotoxins or overexpressing
PD-related genes (Soldner et al, 2009). Thus, it may not appear
entirely unexpected that DAn differentiated from our LRRK2-PD
iPSC displayed PD-related alterations in vitro. However, during
the writing of this manuscript, a study was published that foundwww.embomolmed.org EMBO Mol Med 4, 380–395no alterations in DAn differentiated from iPSC from one LRRK2-
PD patient, unless these were challenged with H2O2, 6-
hydroxydopamine (a PD-related neurotoxin) or MG-132 (pro-
teasome inhibitor; Nguyen et al, 2011). We believe that the lack
of spontaneous PD pathology-related phenotypes in previous
iPSC-based models of ID-PD (Soldner et al, 2009) and LRRK2-PD
(Nguyen et al, 2011), in contrast with our results presented here,
may be due to at least two reasons: First, the longer time span of
cultured neurons (up to 75 days) in our experiments, which may
have induced culture-related stress conditions mimicking in vivo
aging in PD patients, and thus accelerated the development of
PD-related phenotypes in vitro. In support of this, we found that
DAn differentiated for 30 days from ID-PD- or LRRK2-PD iPSC, a 2012 EMBO Molecular Medicine 389
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Figure 7. Defective autophagosome clearance in PD-iPSC-derived DA neurons.
A-C. DAn (TH positive, white) cultured on astrocytes for 75 days stained for LC3 (green) and LAMP1 (red) after 6 h of treatment with leupeptin from CONTROL (cell
line SP11.1, A), ID-PD (cell line SP10.2, B) and LRRK2-PD (cell line SP05.1, C) iPSC. Z-stack views are shown on the merged images (right panels). Nuclei are
counterstained with DAPI, shown in blue. Scale bars, 5mm.
D. Quantitative analyses of the colocalization of LAMP1 and LC3. Data for each group is the average of 15, 15 and 14 DAn representing three different Ctrl-, ID-
PD and LRKK2-PD iPSC lines, respectively. Asterisks denote statistically significant differences between CONTROL and ID-PD (p<0.001) or LRRK2-PD
(p< 0.001) [F(2,41)¼ 41.628; p<0.001].
E. Quantitative analyses of the total neurite length per neuron with or without treatment with rapamycin and leupeptin. Under basal conditions (without
treatment), data for CONTROL is the average of 97 DAn from 4 iPSC lines, for ID-PD is from 127 DAn from 7 iPSC lines and for LRRK2-PD is from 80 DAn from 4
iPSC lines. After treatment with rapamycin and leupeptin (RAPAþ LEUP), data for CONTROL is the average of 60 DAn from 4 iPSC lines, for ID-PD is from 112
DAn from 7 iPSC lines and for LRRK2-PD is from 74 DAn from 4 iPSC lines. Asterisks above data bars denote statistically significant differences under basal
conditions [F(2,301)¼ 5.886; p¼ 0.003] between CONTROL and ID-PD (p¼ 0.003), and between CONTROL and LRRK2-PD (p¼0.022), and after treatment
with rapamycin and leupeptin [F(2,243)¼48.812; p< 0.001] between CONTROL and ID-PD (p<0.001), and between CONTROL and LRRK2-PD (p< 0.001).
Asterisks comparing data sets denote statistically significant differences in total neurite length after treatment with rapamycin and leupeptin in DAn from
ID-PD (p¼0.001) and LRRK2-PD (p< 0.001), but not from CONTROL (p¼0.090). In (D–E) bars represent average with SEM as error bars.
390time when no alterations (other than SNCA accumulation in
LRRK2-PD iPSC-derived DAn) were evident, showed increased
susceptibility to sub-lethal concentrations of the PD-related
toxin MPPþ (Fig S11 of Supporting information). Thus, it is
likely that the prolonged culture of these cells in our 75-day
differentiation protocol served to amplify the intrinsic suscept-
ibility of PD-iPSC-derived DAn to undergo neurodegeneration in
response to aging, the most important PD-related susceptibility 2012 EMBO Molecular Medicinefactor. Second, it should be noted that the majority of iPSC-
derived neurons in our experiments were of vmDA neuron
phenotype, whereas, this cell population was much rarer in
previous studies, with Soldner and colleagues reporting 10%
of DAn (THþ/TUJ1þ cells) of a phenotype that was not
examined in detail (Soldner et al, 2009), and Nguyen and
colleagues reporting less than 1% of neurons of a vmDA
phenotype (Nguyen et al, 2011). We believe that the enrichmentEMBO Mol Med 4, 380–395 www.embomolmed.org
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of PD pathology-related phenotypes, which are known to affect
preferentially this specific subtype of DAn.
Our iPSC-based PD model should help investigating the
pathogenic mechanisms that underlie PD neurodegeneration.
Thus, although several lines of evidence suggest a causal link
between impaired autophagy and the development of PD-
related pathology, definitive proof for this has been elusive
(reviewed in Yang & Mao, 2010). Our findings of defective
autophagosome clearance in DAn from PD patient-specific iPSC,
together with the positive correlation between the expansion of
the autophagic compartment and the degree of morphological
alterations in these cells, provide strong support for this
hypothesis. In addition, the iPSC-based PD model described
here should also prove an invaluable tool to investigate early
functional alterations that predate the onset of neurodegenera-
tion, which surely will help identifying potentially new
therapeutic targets for the prevention, rather than rescue, of
PD-related neurodegeneration.
Overall, our studies demonstrate the potential of iPSC-based
technology to experimentally model the pathogenic mechan-
isms of late-onset diseases such as PD. Not only did we find PD
pathology related phenotypes in long-term cultures of DAn
representing a monogenic form of PD, but also in those from
patients of ID-PD. This critical point indicates that the cause for
the increased susceptibility of ID-PD-derived DAn to undergo
degeneration in vitro after long-time culture, albeit complex, is
encoded in the genome of ID-PD patients, or at least of those
tested in our study. Therefore, intrinsic cell-autonomous factors,
rather than environmental influences, appear to be sufficient to
trigger neurodegeneration of DAn from PD patients, in a process
that requires time to manifest itself, but that can be modelled
within the time-frame of in vitro experiments. We believe that
key aspects to the success of our strategy were the efficient
differentiation of the PD relevant cell type, the ability to
maintain DAn cultures over a long-term culture span and the use
of multiple patients per condition, which allowed controlling the
inherent variability of human pluripotent stem cell lines. In
this way, we have identified in vitro phenotypes associated
with ID and/or LRRK2 PD, which could be harnessed as
readouts for drug screening studies. Our findings provide
important conceptual and technical advances for the under-
standing of PD pathogenesis and, eventually, for the identifica-
tion of novel therapeutic strategies in this disease.MATERIALS AND METHODS
Description of PD patients
Studies were approved by the authors’ Institutional Review Board and
conducted under the Declaration of Helsinki. Patients were encoded to
protect their confidentiality, and written informed consent obtained.
The generation of human iPS cells was done following a protocol
approved by the Spanish competent authorities (Commission on
Guarantees concerning the Donation and Use of Human Tissues and
Cells of the Carlos III Health Institute). PD was diagnosed according to
UK Brain Bank criteria (Hughes et al, 1992). We identified subjectswww.embomolmed.org EMBO Mol Med 4, 380–395participating in the study among patients attending the outpatient
Movement Disorder Unit at the Hospital Clinic of Barcelona
(Barcelona, Spain). Four patients were known from previous studies
to have LRRK2-associated PD. The remaining seven patients had
a sporadic form of PD and LRRK2 mutation was excluded by direct
DNA sequencing. Healthy controls were recruited among patients’
spouses.
Generation of iPSC
Epidermal keratinocytes were used for iPSC generation, except for
patients SP05 and SP09, for whom dermal fibroblasts were used.
Keratinocytes were cultured in serum-free low calcium medium
(Epilife, Invitrogen) and reprogrammed using a 1:1:1 mix of retro-
viruses encoding FLAG-tagged OCT4, SOX2 and KLF4, essentially as
previously described (Aasen et al, 2008). Fibroblasts were repro-
grammed using a 1:1:1 mix of retroviruses encoding FLAG-tagged
OCT4, SOX2 and KLF4, following a previously described protocol (Raya
et al, 2010). For selecting reprogrammed cells, the medium was
changed to human ES cell (hESC) medium, consisting of KO-DMEM
(Invitrogen) supplemented with 20% KO-Serum Replacement (Invitro-
gen), 2mM Glutamax (Invitrogen), 50mM 2-mercaptoethanol (In-
vitrogen), non-essential aminoacids (Cambrex) and 10ng/ml bFGF
(Peprotech). Cultures were maintained at 378C, 5% CO2, with media
changes every other day. Colonies were picked based on morphology
45–60 days after the initial infection and plated onto fresh feeders.
Lines of patient-specific iPS cells were maintained by mechanical
dissociation of colonies and splitting 1:3 onto feeder cells in hESC
medium or by limited trypsin digestion and passaging onto Matrigel-
coated plates with hESC medium pre-conditioned by mouse
embryonic fibroblasts. The iPSC lines generated and characterized in
this study are currently in the process of being registered and
deposited in the Spanish Stem Cell Bank, through which they will be
made available to interested researchers.
Characterization of iPSC lines
Expression of retroviral transgenes and endogenous pluripotency-
associated transcription factors by quantitative Polymerase Chain
Reaction (after reverse transcription) (RT-PCR), integration of retroviral
transgenes by Southern blot and methylation status of OCT4 and
NANOG promoters were assessed as previously reported (Aasen et al,
2008). In vitro differentiation towards endoderm, mesoderm and
neuroectoderm was carried out essentially as described (Raya et al,
2008). Severe combined immunodeficient (SCID) beige mice (Charles
River Laboratories) were used to test the teratoma induction capacity
of patient-specific iPS cells essentially as described (Aasen et al, 2008).
All animal experiments were conducted following experimental
protocols previously approved by the Institutional Ethics Committee
on Experimental Animals, in full compliance with Spanish and
European laws and regulations.
iPSC differentiation to DA neurons
For DAn differentiation, iPSC were transduced with LV.NES.LMX1A.GFP
and processed as previously described (Sanchez-Danes et al, 2011).
For DAn yield analysis cells were co-cultured with PA6 for 3 weeks in
N2B27 medium. For SNCA and LRRK2 staining, DAn generated on the
top of PA6 for 3 weeks were trypsinized and cultured for 3 days on
Matrigel-coated dishes. For long-term culture, neural progenitor cells 2012 EMBO Molecular Medicine 391
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392were seeded onto mouse primary cortical astrocytes, prepared as
described elsewhere (Giralt et al, 2010), and maintained in N2B27
medium. After 9 weeks, some wells were incubated with 4mM
rapamycin (LC Labs) and/or 100mM leupeptin (Sigma) for 6 h prior to
fixation. For LC3 flux studies in DAn, neurons differentiated on murine
astrocytes for 9 weeks were treated for 2 and 4 h with lysosomal
inhibitors NH4Cl (20mM, Sigma) and leupeptin (200mM) in N2B27
media. After the treatment a pellet was obtained using a cell
scraper (BD).
Expression of wild-type or mutant LRRK2 in DAn
DAn differentiated on top of murine astrocytes were grown on
coverslips and transfected at day 65 of the differentiation protocol.
The transfection was done as described previously (Kaech & Banker,
2006). Briefly, transfection media consisting on 200ml of MEM media
(Invitrogen), 5ml lipofectamine 2000 (Invitrogen), 1mg of plasmids
encoding WT LRRK2 or mutant LRRK2G2019S (kindly provided by
Giorgio Rovelli, Novartis Pharma Ltd, Basel, Switzerland, and Philipp
Kahle, Hertie Institute for Clinical Brain Research, University Clinics
Tu¨bingen, Germany) and 0.25mg pmaxGFP plasmid (Lonza) was
prepared. The media was aspirated from the wells and in each
coverslip containing the DAn culture 200ml of transfection media was
added and incubated for 4 h at 378C followed by replacement (two
times) with fresh N2B27 media. GFP positive cells started to appear
2 days after transfection.
Immunohistochemistry
Cells were fixed with 4% paraformaldehyde in PBS at 48C for 10min
and permeabilized for 15min in 0.5% Triton in PBS. Cells were then
blocked in Triton-X100 with 3% donkey serum for 2 h. The following
antibodies were used: mouse anti-Tra-1-81 (Chemicon, MAB4381,
1:100), rabbit anti-Sox2 (Chemicon, AB5603, 1:500), mouse anti-
SSEA-4 (MC-813-70, 1:2) and mouse anti-SSEA-3 (MC-631, 1:2)
from the Developmental Studies Hybridoma Bank at the University of
Iowa, mouse anti-SMA (Sigma, 1:400), mouse anti-Tuj1 (Covance,
1:500), mouse Oct-3/4 (Santa Cruz, 1:100), rabbit anti-a-fetoprotein
(Dako, 1:400), goat anti-Nanog (Everest Biotech; 1:100), goat anti-
FoxA2 (R&D Biosystems, 1:100), rabbit anti-TH (Sigma, 1:1000),
mouse anti-TH (Chemicon, MAB5280, 1:1000), rabbit anti-Girk2
(Sigma, 1:40), rat anti-DAT (Chemicon, MAB369, 1:400), rabbit anti-
cleaved Caspase-3 (Cell Signalling, 1:400), rabbit anti-LC3 (Cell
Signalling, 1:100), mouse anti-LAMP1 (U. Iowa Developmental
Hybridoma Bank, 1:100), rabbit anti-p62 (Enzo Life Sciences,
1:200), chicken anti-GFP (Aves Labs, 1: 500), rabbit anti-LRRK2
(MJFF C41-2, kindly provided by MJFF, 1:100), mouse anti-
chondroitin sulphate (Sigma, 1:400), rabbit anti-Nurr1 (Santa Cruz,
1: 50) and mouse anti-SNCA (Ab-2, Thermo Scientific, 1:1000).
Secondary antibodies used were all the Alexa Fluor Series from
Invitrogen (all 1:500). Images were taken using Leica SP5 confocal
microscope. For quantification of the DAn yield randomly 300 cells
per differentiated aggregate were counted (average 6–8 differen-
tiated aggregates per experiment). Data points represent the average
of at least three-independent experiments. To visualize nuclei, slides
were stained with 0.5mg/ml DAPI (40 ,6-diamidino-2-phenylindole)
and then mounted with PVADABCO. Direct AP activity was analysed
using an AP blue/red membrane substrate solution kit (Sigma)
according to the manufacturer’s guidelines. 2012 EMBO Molecular MedicineNeurite analysis
Neurite analysis was performed at the indicated time-points on iPSC-
derived neurons differentiated on top of cortical mouse astrocytes
fixed and stained for TH. We randomly selected a minimum of 20 DAn
per iPSC line (on the only condition that were isolated from
surrounding DAn, so that we could unambiguously ascribe neurites
to a single DAn), using a Leica SP5 confocal microscope, and analysed
with the ImageJ plugin NeuronJ to determine the number and length
of neurites per cell.
Fibroblast culture and treatment for autophagy studies
Fibroblasts from all patients were cultured in IMDM (Invitrogen)
supplemented with 10% FBS (Gibco) and 2mM Glutamax (Invitrogen).
Fibroblasts were grown until reaching 65–75% confluence, when
they were used as controls or treated for 6 h with rapamycin (0.2
or 2mM) and 100mM leupeptin. After the treatment, some cells
were fixed and analysed by immunofluorescence for LC3 and
the rest was processed as a pellet for Western blot analysis for
LC3. For LC3 flux studies in fibroblasts, cells were treated for 2
and 4 h in supplemented IMDM containing lysosomal inhibitors,
consisting in 20mM NH4Cl (Sigma) and 200mM leupeptin, after
the treatment a pellet was obtained using 0.25% trypsin–EDTA.
Protein extraction and Western blotting
Proteins were extracted using RIPA protein extraction buffer (Sigma)
supplemented with protease inhibitor (Sigma) and phosphatase
inhibitor cocktails (Sigma). In brief, cells were detached from culture
dishes, centrifuged and washed once with cold PBS. Cell pellets were
then resuspended and incubated in RIPA buffer for 20min on ice and
sonicated in one pulse of 5 s at 10% amplitude on ultrasonicator
(Branson Digital Sonifier, Branson Ultrasonics Corporation, Danbury,
CT, USA) to ensure high efficiency of lysis. After centrifugation,
supernatants of total protein extracts were denatured in loading
buffer for 10min at 988C. Proteins were separated using SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and transferred to
PVDF membrane. The membrane was probed with anti-a-tubulin
(Sigma T6074; 1:10,000), anti-LC3 (Cell Signalling; 1:1000) and anti-
LRRK2 (MJFF2 c41-2; 1:50).
Electron microscopy and morphometric analysis
Cells were fixed in 2.5% gluteraldehyde/2% paraformaldehyde in
100mM sodium cacodylate, pH 7.43 (SC) and post-fixed in 1%
osmium tetroxide in SC followed by 1% uranyl acetate. After ethanol
dehydration and embedding in LX112 resin (LADD Research Indus-
tries), ultrathin sections were stained with uranyl acetate followed by
lead citrate. All grids were viewed on a JEOL 100CX II transmission
electron microscope at 80 kV. Morphometric analysis was performed
using ImageJ in 15–20 different micrographs for each condition after
thresholding. Autophagic vacuoles were identified using previously
established criteria (Dunn, 1990; Nixon et al, 2005). Autophagic
vacuoles (vesicles <0.5mm) were classified as autophagosomes when
they met two or more of the following criteria: double membranes
(complete or at least partially visible), absence of ribosomes attached
to the cytosolic side of the membrane, luminal density similar to
cytosol and identifiable organelles or regions of organelles in their
lumen. Vesicles of similar size but with a single membrane (or less
than 40% of the membrane visible as double), luminal density lowerEMBO Mol Med 4, 380–395 www.embomolmed.org
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The paper explained
PROBLEM:
Parkinson’s disease (PD) has a lifetime risk of 2%, making it the
second most common neurodegenerative disease after Alzhei-
mer’s disease. It is associated to a selective loss of dopaminergic
neurons (DAn) from the substantia nigra pars compacta
responsible for controlling body movement. Around 90% of PD
cases are sporadic, while 10% have a familial or genetic origin, of
which mutations in the LRRK2 gene are the most frequent cause.
The pathogenic mechanisms leading to PD are not well
understood, to a large extent owing to the lack of suitable genetic
models of this disease in animals. Therefore, there is an urgent
need for developing reliable experimental models that recapi-
tulate the salient features of PD. Recently, induced pluripotent
stem cells (iPSC) have been used to model human diseases,
although it is currently unclear if this approach would be able to
model age-related diseases.
RESULTS:
We generated iPSC from sporadic PD patients, PD patients with
LRRK2 mutation and healthy controls. All of these iPSC lines were
comparable in their ability to generate DAn, and no major
differences were found in these neurons under conventional
culture conditions, except for increased accumulation of SNCA in
neurons from LRRK2 mutant iPSC. However, when cultured for
over 2.5 months (a condition mimicking aging in vitro), DAn
differentiated from patient-specific iPSC developed evident signs
of neurodegeneration, including fewer and shorter neurites and a
significant increase in apoptotic cells. Most importantly, this
degeneration occurred in neurons from either sporadic PD or
mutant PD, but not from healthy individuals. We then show that
these alterations are caused by a deficient autophagic
machinery.
IMPACT:
We have generated an iPSC-based model for PD that recapitu-
lates key pathological features of PD such as neurodegeneration
and SNCA accumulation in DAn generated from PD-patients. Our
findings indicate that the bases of the increased susceptibility of
DAn to degenerate upon aging in sporadic PD patients should be
encoded in their genome. Moreover, our iPSC-based PD model
provides a valuable tool to investigate the pathogenic
mechanisms of PD, such as altered autophagy, and to screen for
drugs that may prevent or rescue neurodegeneration in PD.than the surrounding cytosol, multiple single membrane-limited
vesicles containing light or dense amorphous material were classified
as autophagolysosomes.
RT-qPCR analyses
Total mRNA was isolated by guanidinium thiocynate–phenol–chloro-
form extraction (TRIzol, Invitrogen) and treated with DNaseI. One
microgram was used to synthesize cDNA with the SuperScript III
Reverse Transcriptase Synthesis Kit (Invitrogen). Quantitative PCR
analyses were done in triplicate on 50ng with Platinum Syber Green
qPCR Super Mix (Invitrogen) in an ABI Prism 7000 thermocycler
(Applied Biosystems). All results were normalized to HPRT and b-2-
microglobulin. The primers used were: B2micro-F, 50-GCCGTGTGAAC-
CATGTGACT-30; B2micro-R, 50-GCTTACATGTCT CGATCCCACTT-30; HPRT-
F, 50-TTATGGACAGGACTGAACGTCTTG-3’ HPRT-R, 50-GCACACAGAGGGC-
TACAATGTG-30 ; NANOG-F, 50-ACAACTGGCCGAAGAATA GCA-30; NANOG-
R, 5 0-GGTTCCCAGTCGGGTTCAC-3 0; FOXA2-F, 5 0-AGACTCCTGC
TTCTTCAAGCACCT-30 ; FOXA2-R, 50-ACTTCCCTGCAACAACAGCAATGG-30;
LRRK2-F, 50-GGGAGCAGATGCCAATCAAGCAAA-30; LRRK2-R, 50-TCCAC-
CAATTT GGGACTGCTCTCT-30; SNCA-F, 50-AGCGGACCTCCACAAGTAAC-
GAAT-30 ; SNCA-R, 50-TTGGCATCTGTCTTCCTCCCAAGT-30; TAU-F, 50-
ACGAAGGCCTGAAGCACA GGATTA-30; TAU-R, 50-TCCTTTGGGACTGCCAT-
GAGACTT-3’.
Statistical analysis
Differences among groups were evaluated by one-way ANOVA, and
comparisons between two groups by Student’s t-test, using the
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